idea-010 · human · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The one-paragraph version. A disposable test strip and a handheld reader that measure potassium and creatinine from a single fingerstick drop, for use by clinic staff during the visit. The problem it addresses is narrow and real: heart-failure and kidney-disease patients are put on RAAS-inhibitor drugs that have to be dose-titrated against their potassium, and today that means sending the patient for a venous blood draw and waiting for the lab, so the dose decision happens days later or not at all. The distinctive engineering choice is a third channel that does nothing but detect whether the sample was damaged during collection — a fingerstick squeezes red cells and releases potassium, which reads as a falsely high result — and suppresses the potassium value rather than reporting it. It is aimed at outpatient clinics, not emergency or dialysis settings, and would be billed through the existing clinical laboratory fee schedule rather than a new code.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Download the public CMS Clinical Laboratory Fee Schedule and put its potassium and creatinine allowables next to an internal bill-of-materials estimate for the strip — the viability deck's own words are "one free public CMS download and one internal bill-of-materials estimate", and it is the only load-bearing condition here that can be answered before any strip exists, any clinician is interviewed, or any patent is searched. Selected from the Reimbursement and Capital-intensity rows of the Scores table; this is a selection from that gap analysis, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 6 of 43 claims verified, 9 of 9 factors carrying a score, 4 of 4 core factors scored. No claim in this file is refuted and no kill condition fired. Read the gaps carefully, because most of them are tooling rather than findings: the Reimbursement claims are unconfirmed because data/hcpcs_level_ii.csv and data/hcpcs_payment_rates.csv are absent and nothing was searched, not because a code was looked for and missed; the FTO claims are unconfirmed because PATENTSVIEW_API_KEY is unset and no patent search has ever run on the rubric's one automatic-kill factor. Both are human-only unblocks. The two conditions that no tooling in this repo can ever settle — whether a prescriber acts on the result, and the invalid-result rate in ordinary hands — need primary research, and the adoption connector returns unverifiable for exactly that reason rather than guessing.
| Intended use | For the quantitative measurement of potassium and creatinine in fingerstick capillary whole blood by trained healthcare personnel at the point of care in outpatient clinics, as an aid in monitoring adults with chronic heart failure or chronic kidney disease during initiation and dose titration of renin-angiotensin-aldosterone system inhibitors; not for use in emergency, critical-care, or dialysis-adequacy decision-making. |
|---|---|
| Mechanism | Disposable electrochemical test strip taking a single fingerstick capillary drop, with a potassium-selective (ionophore-membrane ISE) channel, an enzymatic creatinine channel, and a third optical/electrochemical hemoglobin channel whose sole job is to detect sample hemolysis and suppress the potassium result rather than report a falsely elevated one; results read on a handheld meter and pushed to the ordering clinic |
| Device class | # An IVD measuring two analytes can carry two generic types and two; Class II — 21 CFR 862.1600 ("Potassium test system"), product code CEM per the; Generator's web search — 510(k), most likely via FDA's Dual 510(k) and CLIA Waiver by; Application pathway — launch designation. No specific predicate K-number identified for; a strip-based fingerstick potassium meter (see claims).; Class II — 21 CFR 862.1225 ("Creatinine test system"), product code CGL — the creatinine; channel is a separate generic type, not a feature of the potassium device. Carried; because a two-analyte meter may need both codes and two predicate arguments in one; submission, which is a real cost and schedule difference, not a filing detail.; OTC / prescription-home-use route — same two regulations, different intended use. NOT; live at launch. Becomes live if the device is labeled for patient self-testing at home,; which adds lay-user comprehension and untrained-operator evidence. Carried because; at-home titration is the obvious product extension and should be a visible regulatory; decision rather than a surprise. |
| Predicate or analog | K070068 — "Nova StatSensor Creatinine Hospital Meter, Control Solutions,; Linearity Solutions, and Test Strips" (Nova Biomedical), decision; 2007-05-07, regulation 862.1225, product code CGL — found via web search; as a real FDA 510(k) record and cited as the closest format analog; (strip + handheld meter + fingerstick volume) and a plausible predicate; for the creatinine channel only. No specific predicate identified for; the potassium channel. Analyzer-format analogs named by web search only:; Abbott i-STAT CHEM8+ cartridge (cleared, CLIA moderate complexity) and; the Abaxis/Abbott Piccolo Xpress (CLIA-waived rotor analyzer). |
| Launch jurisdiction | US |
| Target | human |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 2 | python3 -m connectors regulation 862.1600 --expect "potassium" — and read the identification for the specimen matrix, not just the analyte word; whether capillary whole blood sits inside this generic type is the decisive line. Then…the rest of this gap analysisregulation 862.1225 --expect "creatinine", classification --product-code CEM (recovery query classification --device-name "potassium" if CEM misses), classification --product-code CGL. Predicate anchor: clearance-summary K070068 --expect-indication "creatinine" (K-number-keyed, the right call here) with 510k "StatSensor Creatinine" --applicant "Nova Biomedical" to surface the record itself — note 510k is device-name-keyed, so a bare K-number is a search string, not a lookup. Also run the lead 510k for K091547's device name. The query that actually moves this factor: 510k "potassium meter" and classification --device-name "potassium" to find any strip-format fingerstick potassium predicate, and if that is null, denovo "potassium test system" — that 510(k)-vs-De Novo fork drives Factors 1 and 7 together. An openFDA null is a null, not proof no such device exists. The Dual 510(k)/CLIA Waiver guidance is structurally unreadable here (no connector reads FDA guidance); a human must attach the named PDF, and CLIA's own waiver criteria are checkable via regulation 493.15 --title 42. |
| Reimbursement pathway | 2 | Descriptors for 84132/82565 and the QW rules need a human-attached licensed source: AMA CPT Professional 2026, or a licensed vendor feed (AMA CPT API, Optum EncoderPro, Find-A-Code), recorded as a manual citation. Do not cite…the rest of this gap analysisconnectors cpt 84132 as a check — its unverifiable is by design and means nothing either way. Publicly checkable in parallel, code-keyed and licence-free: the CMS Clinical Laboratory Fee Schedule annual file (public download into data/) for the national limitation amount on 84132 and 82565 — this is the number the whole business case hangs on. Note payment 84132 reads data/hcpcs_payment_rates.csv, a HCPCS/PFS rate cache that may not carry CLFS at all, so an unconfirmed there is a missing-file result and not a finding of low or absent payment; hcpcs 84132 for descriptor-level HCPCS text. Coverage: coverage 84132 plus a named-LCD search of the CMS Medicare Coverage Database for point-of-care potassium or POC chemistry. Waived-billing leg: the CMS CLIA waived-test transmittal list (public, human download) for whether 84132QW/82565QW are genuinely on it, and regulation 493.15 --title 42 for the certificate rules. Strip COGS is a Tier 3 human number; no connector returns it. |
| TAM | 2 | procedures 84132 and procedures 82565 — expect unconfirmed in this deployment (no cached CMS Part B utilisation file); a human supplies the CMS Medicare Part B National Summary Data File or the Physician & Other Practitioners PUF…the rest of this gap analysisintodata/. When it resolves, filter to office place-of-service (POS 11) and read it as a Medicare-FFS floor, never as TAM — the unfiltered number is dominated by central-lab volume this device cannot take. Price: the CLFS allowable above plus a Tier 3 strip-COGS estimate; connectors market is unverifiable by design. Denominator: a count of US outpatient HF/cardiology and nephrology clinics from Medicare provider enrolment (PECOS / Provider Enrollment PUF) by specialty, or a licensed POC-diagnostics / clinical-chemistry market report (iData, Kalorama) attached by a human. Switching share needs a published preference or adoption study, or a commissioned practice survey; connectors adoption is unverifiable by design and must not be cited as having checked it. |
| FTO / IP | 1 | A real search first, by a human or Scout in Patents Public Search / Espacenet, to produce numbers: CPC G01N27/333 (ion-selective electrodes / potassium), G01N33/49 (blood analysis) and G01N33/72 (haemoglobin), C12Q1/00 enzymatic…the rest of this gap analysiscreatinine, plus G01N27/327 biosensor-strip art; assignee sweeps on Nova Biomedical, Abbott Point of Care, Roche Diagnostics, Siemens Healthineers and i-SENS. The single highest-value query is art on haemoglobin or haemolysis detection used to flag or suppress a co-located electrolyte result — a live, enforceable claim there sits directly on this candidate's only differentiator and is an automatic kill if unworkable-around. Each candidate number then throughpython3 -m connectors patent US<number> for family, legal status and expiry, which requires PATENTSVIEW_API_KEY to be set in this deployment first. Definitive answer is a Tier 3 legal FTO opinion at Stage 7. |
| Moat / defensibility | 2 | Not settleable by a lookup; it resolves as a by-product of the Factor 4 search. A filed or filable claim set over the haemolysis-suppression logic and the membrane formulation is the only thing that converts asserted know-how into an asset…the rest of this gap analysis— Patents Public Search to find whether that space is open, thenconnectors patent US<number> on what is found. Direct read on copyability: clearances --product-code CEM --since 5y and clearances --device-name "potassium" --since 5y for how quickly followers clear comparable devices (Stage 0 scan, no confidence tag — a pointer, not a verification). The trade-secret leg (yield curve) is undocumentable by any lookup and is Tier 3 diligence. |
| Mechanism & clinical risk | 1 | No connector can settle this. Definitive answer is bench work at Stage 7: a **paired capillary-versus-venous method comparison across multiple ordinary operators with a deliberate lysis challenge, reporting the invalid/suppressed-result…the rest of this gap analysisrate as a primary endpoint alongside bias** — not a clean-sample accuracy study. Cheapest first look, and it should happen before anything else in this file:literature "capillary potassium hemolysis" --since 10y and literature "pseudohyperkalemia capillary sampling", then literature-detail <PMIDs> — published capillary-vs-venous potassium bias and haemolysis rates very likely already quantify this failure, and if they do, the number is decisive either way. Also trials --condition "hyperkalemia" --intervention "point-of-care potassium" then trial-detail <NCT>; recalls --product-code CEM for real-world potassium-measurement failure signal on cleared devices. Strong indirect evidence available now: run clearance-summary on any cleared POC potassium device Factor 1 turns up and read whether its Indications for Use excludes capillary specimens — an incumbent labelling capillary out is the market telling you the problem is unsolved. Note every one of these is a Stage 0 scan carrying no confidence tag; they point at evidence, they do not verify the claim. |
| Capital intensity & time-to-revenue | 1 | Depends on Factor 1 resolving the 510(k)-versus-De Novo fork first (510k "potassium meter" / denovo "potassium test system" / classification --device-name "potassium" as above) — that fork, not the study design, is the dominant term…the rest of this gap analysisin both cost and calendar. Then scope the required evidence package from the special controls inregulation 862.1600 and regulation 862.1225, and the waiver burden from regulation 493.15 --title 42 plus the human-attached FDA Dual 510(k)/CLIA Waiver by Application guidance (no connector reads guidance documents). Study size and duration proxies from trial-detail <NCT> on comparable POC method-comparison studies. The dollar figures — strip-line capex, per-site study cost, submission cost — are Tier 3 human estimates; no connector returns submission cost or review time, and any number an agent supplies here is invented. |
| Competitive intensity | 1 | clearances --product-code CEM --since 5y and clearances --product-code CGL --since 5y for who has cleared what and the trend, plus clearances --device-name "potassium" --since 5y; recalls --product-code CEM and `--firm "Nova…the rest of this gap analysisBiomedical" for incumbent trouble. These are Stage 0 scans and return no confidence tag — pointers, not verifications. The waived-test leg: the CMS CLIA waived-test transmittal list (public, human download into data/) for whether 84132QW is genuinely listed and against which analyzers — that single document either confirms or refutes the premise-correcting claim and it is the cheapest thing here to settle. The switching leg — whether a clinic that already owns a Piccolo or sends to an outside lab would buy a strip meter — is not connector-answerable: connectors adoption is unverifiable by design, and it needs a licensed POC-diagnostics report or a commissioned HF/nephrology practice survey attached by a human. Do not let a clean clearances` result stand in for it. |
| Strategic fit & portfolio balance | 2 | Not a connector question and not an agent question. Settled by a Tier 3 human portfolio statement at Stage 6 review (## Human Review Notes): current hero-bet versus spoke mix, whether capital exists for a multi-year manufacturing-heavy…the rest of this gap analysisprogramme, and appetite for consumable-margin businesses.knowledge-base/calibration-log.md is the evidence base for scoring this factor systematically and is currently empty; that emptiness is information about the pipeline, not an obstacle to route around. |
All six wrap criteria are met.
Domain dossier: potassium-monitoring-ckd
Source file: knowledge-base/candidates/idea-010.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.